실시간
Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsFierceBiotechBiopharma moves to reduce development risk earlier than everFierceBiotechIncyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaEndpoints News#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotFierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection pointFierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regressionLabiotechTop biotech deals in May 2026PharmaVoice3 potential takeover targets in obesityFierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-making
Endpoints News 2025년 12월 22일

Windward gets bispecific from Qyuns in its second China deal of the year

Windward gets bispecific from Qyuns in its second China deal of the year

본문을 이용할 수 없습니다. 원본 출처를 확인하세요.